ArticlePLoS computational biology2019
Cancer recurrence times from a branching process model.
Article in PLoS computational biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Review
- Quantifying Direct and Indirect Effects through Joint Modeling of Terminal Events and Gap Times between Recurrent Events.Journal of data science : JDS · 2026Article
- Article
- Accumulation of Oncogenic Mutations During Progression from Healthy Tissue to Cancer.Bulletin of mathematical biology · 2024Article
- Mathematical Model of Intrinsic Drug Resistance in Lung Cancer.International journal of molecular sciences · 2023Article
- Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics.Cancer research · 2023Article
- Sequential mutations in exponentially growing populations.PLoS computational biology · 2023Article
- A multispecies framework for modeling adaptive immunity and immunotherapy in cancer.PLoS computational biology · 2023Article
- Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.Tomography (Ann Arbor, Mich.) · 2023Review
- Cancer's second genome: Microbial cancer diagnostics and redefining clonal evolution as a multispecies process: Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution: Humans and their tumors are not aseptic, and the multispecies nature of cancer modulates clinical care and clonal evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2022Review
- AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.Molecular medicine reports · 2022Article
- Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response.Immunoinformatics (Amsterdam, Netherlands) · 2021Article
- Epigenetic instability may alter cell state transitions and anticancer drug resistance.PLoS computational biology · 2021Article
- Overcoming Chemoresistance via Extracellular Vesicle Inhibition.Frontiers in molecular biosciences · 2021Review
- A mathematical model of the metastatic bottleneck predicts patient outcome and response to cancer treatment.PLoS computational biology · 2020Article
- Implications of immune-mediated metastatic growth on metastatic dormancy, blow-up, early detection, and treatment.Journal of mathematical biology · 2020Article
- Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As cancer advances, cells often spread from the primary tumor to other parts of the body and form metastases. This is the main cause of cancer related mortality. Here we investigate a conceptually simple model of metastasis formation where metastatic lesions are initiated at a rate which depends on the size of the primary tumor. The evolution of each metastasis is described as an independent branching process. We assume that the primary tumor is resected at a given size and study the earliest time at which any metastasis reaches a minimal detectable size. The parameters of our model are estimated independently for breast, colorectal, headneck, lung and prostate cancers. We use these estimates to compare predictions from our model with values reported in clinical literature. For some cancer types, we find a remarkably wide range of resection sizes such that metastases are very likely to be present, but none of them are detectable. Our model predicts that only very early resections can prevent recurrence, and that small delays in the time of surgery can significantly increase the recurrence probability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.